OncoMatch/Clinical Trials/NCT06686394
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Is NCT06686394 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for breast neoplasms.
Treatment: Patritumab deruxtecan · Trastuzumab · Trastuzumab Biosimilar · Pertuzumab · Tucatinib — Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (HER2+)
Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute ( Site 0050) · Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey ( Site 0052) · New Brunswick, New Jersey
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) · Greenville, South Carolina
- Inova Schar Cancer Institute ( Site 0051) · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify